

Curcumin C3 Complex[®] **Modifies** Lipids in Metabolic Syndrome



THEORY:

METABOLIC SYNDROME AFFECTS

millions of people globally. It involves simultaneous occurrence of several

risk factors, such as hypertension, hyperglycemia, abdominal obesity and atherogenic dyslipidemia. Since there is a cluster of risk factors, the benefits of targeted drugs (such as statins used for the management of dyslipidemia) are limited. However, there may be a role for natural alternatives like curcumin with multifactorial effects, including activity against inflammation, oxidative stress, hypertension, hyperglycemia and insulin resistance.

PARAMETERS:

IN A RANDOMIZED, double-blind, placebocontrolled study in 100 patients diagnosed with metabolic syndrome on standard treatment, half the participants received 1,000 mg/d of Sabinsa's Curcumin C3 Complex[®] in combination with natural bioavailability enhancer Bioperine[®] (a standardized extract of black pepper from Sabinsa) and the other half received placebo for eight weeks. Serum concentrations of total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglyercides, small dense LDL (sdLDL) cholesterol, lipoprotein(a) [Lp(a)] and non-HDL cholesterol were determined at baseline and at the end of the eight-week treatment period.



OUTCOME:

CURCUMINOIDS

(as Curcumin C3 Complex) were found to be more effective than placebo in reducing

- serum LDL cholesterol
- triglycerides
- non-HDL cholesterol
- total cholesterol
- Lp(a)

The intervention also helped to **ELEVATE HDL** CONCENTRATIONS.

THE EFFECTS OF CURCUMINOIDS on non-HDL cholesterol, total cholesterol, triglycerides and Lp(a) remained significant after adjustment for baseline values of lipids and body mass index (BMI).



IMPACT:

Metabolic syndrome affects about 23 percent of U.S. adults and places them at higher risk of cardiovascular disease (CVD), diabetes, stroke and diseases related to fatty buildups in artery walls.¹ As increasing evidence suggests a relationship between metabolic syndrome and mortality,² solutions are needed to help target common risk factors such as high levels of triglycerides and "bad" (LDL) cholesterol. A natural option such as curcuminoids with enhanced bioavailability could provide an adjunctive controlling influence on lipid profile of subjects with metabolic syndrome on standard treatment.

SABINSA CORPORATION

- 1. American Heart Association, 2016, heart.org
- 2. Medicine, 2017:96(45):e8491.

Source: Panahi Y et al. "Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial." Complement Ther Med. 2014;22(5):851-7. DOI: 10.1016/j. ctim 2014 07 006